The existence and localization of brain angiotensin receptors is well established. However, questions regarding the endogenous ligand for brain angiotensin type 1 (AT 1 ) receptors necessitates re-examination of brain angiotensin receptor binding studies. To assess the ability of angiotensin II to bind to the brain AT 1 receptor, radioligand binding studies of rat brain AT 1 receptors were performed using both 125 I-angiotensin II and 125 I-sarcosine 1 , isoleucine 8 angiotensin II. Determination of binding kinetics and competition by an AT 1 receptor antagonist was carried out to reveal the identity of the membrane binding sites and to identify the bound 125 I-labeled molecules. Initial analysis of 125 I-angiotensin II binding to hypothalamic membranes using an established protocol revealed that a negligible amount of intact radioligand was bound to the membranes. In contrast, binding of 125 I-sarcosine 1 , isoleucine 8 angiotensin II was saturable, of high affinity, and primarily as intact radioligand. Sequential addition of four peptidase inhibitors-ophenanthroline, puromycin, phenymethylsulfonyl fluoride, and glutamate phosphonate-to the assay buffer dramatically increased the binding of 125 I-angiotensin II to rat brain membranes: more than 75% of the bound 125
contrast, binding of 125 I-sarcosine 1 , isoleucine 8 angiotensin II was saturable, of high affinity, and primarily as intact radioligand. Sequential addition of four peptidase inhibitors-ophenanthroline, puromycin, phenymethylsulfonyl fluoride, and glutamate phosphonate-to the assay buffer dramatically increased the binding of 125 I-angiotensin II to rat brain membranes: more than 75% of the bound 125 I was the intact radioligand, and the binding was of high affinity and saturable. Some, but not all, of the binding could be displaced by the AT 1 -selective antagonist losartan. This demonstrates that 125 Iangiotensin II can bind to brain AT 1 receptors and does not require conversion to 125 I-angiotensin III to bind to brain AT 1 receptors.
After the discovery of the brain renin-angiotensin system (Ganten et al., 1971) , angiotensin (Ang) II binding sites in rat (Glossmann et al., 1974) and bovine brains were observed (Bennett and Snyder, 1976) . Angiotensin receptors occur in the brains of other species (Harding et al., 1981; Speth et al., 1985; Allen et al., 1987) , including human (Allen et al., 1987) . In vitro autoradiographic studies have localized angiotensin receptor binding sites to specific brain nuclei (Mendelsohn et al., 1984; Speth et al., 1985) . Both AT 1 and AT 2 subtypes occur in the brain (Rowe et al., 1990) . However, these studies faced a major pitfall-metabolic degradation of the radiolabeled angiotensin, which precludes accurate measurement of binding assays .
There were two major problems: 1) inability to reach steady-state conditions-the time course for binding of radioligand was bell-shaped; and 2) angiotensin fragments, along with intact radioligand, bound specifically (Harding et al., 1986; Abhold et al., 1987; Abhold and Harding, 1988) . The reduction of 125 I-Ang III binding when its degradation to 125 I-des Asp 1 ,des Arg 2 Ang II ( 125 I-Ang IV) was inhibited contributed to the discovery of a novel binding site for Ang IV (Harding et al., 1992; de Gasparo et al., 2000) now known to be insulin-regulated aminopeptidase (Albiston et al., 2001) .
Approaches used to overcome metabolic degradation of angiotensins during binding studies included 1) addition of protease inhibitors to the incubate, e.g., sulfhydryl reagents (dithiothreitol and ␤-mercaptoethanol), chelating agents (EDTA, EGTA, and o-phenanthroline) , pure protease inhibitors (leupeptin, pepstatin, bacitracin, amastatin, bestatin, and phenylmethylsulfonyl fluoride), and unrelated peptides (glucagon, insulin, and bovine serum albumin) (Glossmann et al., 1974; Bennett and Snyder, 1976; Abhold et al., 1987; Abhold and Harding, 1988) ; 2) use of purified plasma membranes to avoid receptor-mediated endocytosis (Harding et al., 1986) ; and 3) development of peptidase-resistant antagonist analogs of angiotensins, e.g., sarcosine 1 substituted for aspartic acid 1 to provide metabolic stability against acid aminopeptidases (Regoli et al., 1974) .
These approaches partly protected angiotensin ligands from degradation; however, none of the approaches alone or in combination has been completely successful (Regoli et al., 1974; Abhold et al., 1987; Karamyan and Speth, 2007) . Moreover, studies of the identity of brain membrane-bound 125 I derived from 125 I-Ang II predated the discovery of multiple Ang II receptor subtypes (Chiu et al., 1989; Whitebread et al., 1989) . Thus, it is not known whether the intact 125 I-Ang II was bound to the AT 1 receptor, the AT 2 receptor, or both. An additional concern is that the sarcosine 1 analog or the isoleucine 8 analog (Marshall et al., 1970) may not fully represent agonist binding of natural sequences to angiotensin receptors. Sarcosine (N-methyl glycine) is devoid of a side chain in contrast to the bulky alkyl carboxylate moiety of aspartic acid. Thus, sarcosine 1 Ang II may better mimic Ang III than Ang II (Wright et al., 1989) . This takes on great importance considering the ongoing debate regarding the main effector peptide of the brain renin-angiotensin system-Ang II versus the heptapeptide Ang III (Harding and Felix, 1987; Zini et al., 1996; Kokje et al., 2007; Bodineau et al., 2008; Speth and Karamyan, 2008) . Moreover, if only Ang III can activate brain AT 1 receptors (the angiotensin III hypothesis), then Ang II either does not bind to AT 1 receptors in the brain, or it binds to the brain AT 1 receptors without causing a response (Kokje et al., 2007; Speth and Karamyan, 2008) .
Because receptor binding studies require that ligand and receptor metabolism does not occur (Bennett, 1978) , binding assays using 125 I-Ang II must document that specifically bound radioligand is unchanged. If the 125 I-Ang II is metabolized to 125 I-Ang III, this could support the hypothesis that Ang III is the active angiotensin in the brain (Abhold and Harding, 1988; Bodineau et al., 2008) .
The purpose of this study was 2-fold: first, to establish experimental conditions using protease inhibitors to protect 125 I-Ang II from metabolic degradation; and second, to determine whether Ang II must be converted to Ang III to bind to rat brain AT 1 receptors. Metabolic studies determined the effectiveness of the protease inhibitors in protecting 125 I-Ang II from degradation during the binding assays. Dithiothreitol and other sulfhydryl-reducing agents previously used to inhibit 125 I-Ang II from degradation (Glossmann et al., 1974; Bennett and Snyder, 1976) were not used because they impair AT 1 receptor binding (Chiu et al., 1989; Speth et al., 1991) .
Binding of radioiodinated Ang II to the brain AT 1 receptor was compared with that of sarcosine 1 , isoleucine 8 Ang II (SI Ang II), considered to be the standard for angiotensin receptor binding studies. In addition, the binding of radioligands to the liver AT 1 receptor assessed possible differences in their affinities and possible negative effects of protease inhibitors.
Materials and Methods
Adult Sprague-Dawley rats (Harlan, Indianapolis, IN), weighing 300 to 350 g, were used for this study. Rats were maintained under a 12-h light/dark cycle and fed ad libitum. The protocol for these experiments was approved by the University of Mississippi Institutional Animal Care and Use Committee.
Ang II and SI Ang II were obtained from Phoenix Pharmaceuticals (Belmont, CA). Fragments of the angiotensins were purchased commercially or synthesized by Dr. Gerhard Munske (Washington State University, Pullman, WA). AT 2 receptor antagonist PD123319 was purchased from Tocris Bioscience (Ellisville, MO), and AT 1 receptor antagonist losartan was from Sigma-Aldrich (St. Louis, MO). Glutamate phosphonate (4-amino-4-phosphonobutyric acid; GluP) was synthesized in house or by Thesis Chemistry (Mentor, OH). In brief, the in-house procedure was as follows: the GluP precursor ester methyl-3-(ethoxyphosphono)-3-aminopropanoate was synthesized in three steps from readily available ethyl-4-chloro-4-oxobutyrate (Kowalik et al., 1981) and subsequently treated with 9 N HCl under reflux for 20 h. The product was precipitated with methanol/propylene oxide (Oleksyszyn and Tyka, 1977) and recrystallized from ethanol, yielding GluP (Genet et al., 1992) . Glutamate thiol was a kind gift from Dr. Sherwin Wilk (Mount Sinai School of Medicine, City University of New York, New York, NY). JA-2 was a kind gift from Dr. A. Ian Smith (Baker Heart Research Institute, Melbourne, Australia). The rest of the protease inhibitors were obtained from commercial suppliers. Ang II, SI Ang II, and fragments of these angiotensins were radiolabeled with 125 I by the chloramine-T procedure in-house, and the monoradioiodinated angiotensin was purified by HPLC (Speth and Harding, 2001) .
Binding of 125 I-Ang II and 125 I-SI Ang II in rat hypothalamic and liver membranes was measured using established procedures (Speth, 2003) . In brief, rat liver and brain were excised upon decapitation, and the hypothalamus was quickly dissected from the brain (Glowinski and Iversen, 1966) . Tissues were weighed and immediately homogenized in ice-cold hypotonic, 20 mM NaPO 4 , pH 7.2, solution by a mechanical homogenizer (Tissuemizer; Tekmar-Dohrmann, Mason, OH). The homogenates were centrifuged (40,000g for 20 min at 4°C), and the supernatants were decanted. The membrane pellets were resuspended by homogenization in initial assay buffer (150 mM NaCl, 5 mM EDTA, 0.1 mM bacitracin, and 50 mM NaPO 4 , pH 7.1-7.2). The homogenates were recentrifuged as described above, and the pellets were resuspended by homogenization in the assay buffer (50 mg/ml initial wet tissue weight for hypothalamus and 20 mg/ml for liver). PD123319 was added into hypothalamic membrane suspension as a 1/1000 dilution from 10 mM stock in water. For evaluation of the ability of additional protease inhibitors to inhibit radioligand degradation, the inhibitors were added to membrane suspensions to obtain the desired final concentrations from 50 to 400 mM working stocks at least 10 min before incubation with radioligands.
Saturation binding studies were carried out by incubation of 50 l of membrane preparation with six concentrations of 125 I-Ang II (0.3-6 nM) and 125 I-SI Ang II (0.25-3 nM) in 100 l of total assay volume for 1 or 2 h at 24°C, respectively. The incubation times are based on time course analyses indicating maximal specific binding at 60 min for 125 I-Ang II and near-equilibrium binding at 2 h for 125 I-SI Ang II in hypothalamic membranes (data not shown). jpet.aspetjournals.org hypothalamic or liver membrane suspensions (equal to 12.5 and 5 mg initial wet weight, respectively) in 500 l of assay buffer were incubated with ϳ1 nM 125 I-Ang II or 125 I-SI Ang II at 24°C for 1 or 2 h, respectively. Incubation was stopped by centrifugation at ϳ13,000g for 3 min, and the supernatant was discarded. The pellet was resuspended in HPLC mobile phase: 21% acetonitrile/79% triethylamine phosphate (83 mM phosphate, pH 3.0), periodically vortexed during a 20-min extraction period, and recentrifuged. The supernatant was filtered through a 0.22-m filter, applied to Sep-Pak (Waters, Milford, MA) C18 column, and eluted with 21% acetonitrile/79% triethylamine phosphate (83 mM phosphate, pH 3.0). The eluate (ϳ99% recovered radioactivity) was evaluated by HPLC using a reversephase (C18) column with a mobile phase of either 13% acetonitrile/ 87% triethylamine phosphate (83 mM phosphate, pH 3.0), to resolve smaller fragments, or 21% acetonitrile/79% triethylamine phosphate (83 mM phosphate, pH 3.0) at a flow rate of 1.2 ml/min. Radiolabeled Ang II, SI Ang II, and fragments were identified based on the elution times of radioiodinated angiotensin fragment standards as monitored using a flow-through radioiodine detector (model 170; Beckman Coulter, Fullerton, CA) under the same HPLC conditions. Fifteen-second fractions of the column eluates were collected and counted in a ␥-counter to calculate the ratio of peaks corresponding to angiotensins and fragments relative to the total amount of radioactivity applied for HPLC analysis. Values reported are mean percent Ϯ S.E.M.
Results
The identity of the 125 I-labeled material bound to hypothalamic and liver membranes with incubation of 125 I-Ang II and 125 I-SI Ang II in the initial assay buffer, with no additional protease inhibitors, after 1-and 2-h incubation at 24°C, respectively, is summarized in The addition of 1 mM o-phenanthroline and 3 mM puromycin dramatically improved the specific binding of 125 I-Ang II (Fig. 1bЈ) to the hypothalamic membrane preparation. The metabolic profile was also markedly changed (Fig. 1b) . The binding was now predominantly made up of 125 I-Ang III (26.3 Ϯ 1.5%), the des Asp 1 des Phe 8 hexapeptide [Ang (2-7)] fragment (31.1 Ϯ 0.6%), and intact 125 I-Ang II (19.7 Ϯ 3.0%). The B max value was substantially increased, whereas the K d value (1.9 nM) revealed a high-affinity specific binding (Fig.  1bЈ) .
The effects of puromycin and o-phenanthroline on 125 I-Ang II metabolism were not determined individually in this study. However, a previous study (Saylor et al., 1993) reported that the addition of o-phenanthroline plus bovine serum albumin to assay buffer protected unbound 125 I-SI Ang II from metabolic degradation and substantially increased 125 I-SI Ang II binding to brain AT 1 receptors on slide-mounted sections of rat brain. Moreover, the superiority of EDTA plus o-phenanthroline against either of the inhibitors alone in protecting 125 I-Ang IV and increasing its binding affinity also has been convincingly demonstrated (Laeremans et al., 2005) .
The addition of 1 mM phenylmethylsulfonyl fluoride (PMSF) to the hypothalamic membrane preparation along with puromycin and o-phenanthroline further increased the specific binding of 125 I-Ang II (Fig. 1cЈ) . It also blocked the formation of the des Asp 1 , des Phe 8 hexapeptide [Ang (2-7)] metabolite of 125 I-Ang II. In the presence of these three added peptidase inhibitors, 125 I-Ang III made up 57.7 Ϯ 2.7% of the binding to hypothalamic membranes, whereas 125 I-Ang II made up 27.5 Ϯ 3.5% (Fig. 1c) .
Addition of the aminopeptidase A inhibitor glutamate phosphonate (Lejczak et al., 1993; Vazeux et al., 1997) to the hypothalamic membrane preparation along with puromycin, o-phenanthroline, and PMSF did not increase specific binding of 125 I-Ang II or change its K d value (Fig. 1dЈ) . However, it substantially increased the proportion of intact 125 I-Ang II bound to the hypothalamic membranes to 75.6 Ϯ 3.2%, while simultaneously reducing the proportion of 125 I-Ang III bound to the hypothalamic membranes to 10.8 Ϯ 1.3% (Table 3 ; Fig.  1d ). Addition of the four peptidase inhibitors to liver membrane preparations improved the protection of 125 I-Ang II and 125 I-SI Ang II from metabolic degradation to more than 95% (Table 3) . Fig. 2 ). To further confirm that the estimated specific binding of 125 I-Ang II and 125 I-SI Ang II in hypothalamic membranes was to the AT 1 receptor, the observed binding (in the presence of four additional protease inhibitors and PD123319) was compared with specific binding of radioligands under the same experimental conditions plus 10 M losartan (specific AT 1 receptor antagonist). This comparison revealed that only a part of the specific binding of 125 I-Ang II (ϳ38% of total specific binding; B max ϭ 0.19 Ϯ 0.03 fmol/mg wet weight; K d ϭ 2.0 Ϯ 0.31 nM) and 125 I-SI Ang II (ϳ33% of total specific binding; B max ϭ 0.25 Ϯ 0.01 fmol/mg wet weight; K d ϭ 0.3 Ϯ 0.08 nM) in hypothalamic membranes was losartan displaceable, i.e., AT 1 receptor binding (Fig. 3, a and b) .
In the liver, in the presence of all protease inhibitors, virtually all specific binding of 125 I-Ang II and 125 I-SI Ang II was losartan displaceable (Fig. 3, c and d) . Several other peptidase inhibitors and amino acids were tested for their ability to protect 125 I-Ang II from metabolic degradation (Table 4). None of these inhibitors improved the binding of 125 I-Ang II to hypothalamic membranes beyond that seen with the initial assay buffer at the concentrations used.
Discussion
Binding and metabolism experiments were carried out with 125 I-Ang II and 125 I-SI Ang II in rat brain hypothalamic membranes, with a goal of developing an assay protocol ensuring protection of the radioligands with no impairment of binding to the AT 1 receptor. Initial and final (in the presence of additional protease inhibitors) assay conditions also were used to estimate metabolism and binding of the radioligands in liver membranes.
Under initial experimental conditions (assay buffer with no additional protease inhibitors) virtually all of the bound radioactivity derived from 125 I-Ang II in hypothalamic membranes consisted of fragments of the peptides, primarily free 125 I-Tyr (Table 1) . Notably, under these assay conditions, there was no significant saturable binding of 125 I-Ang II in hypothalamic membranes. In contrast, more than half of the bound radioligand arising from 125 I-SI Ang II was intact 125 I-SI Ang II, and the binding displayed a high affinity and saturability as seen in previous studies (Rowe et al., 1992; Speth, 2003) . Also noteworthy was the stability of 125 I-Ang II in the liver membrane preparation in which the majority of the bound 125 I was intact 125 I-Ang II, and the binding displayed high affinity and saturability equivalent to that seen for 125 I-SI Ang II. Thus, it is clear that the hypothalamic membrane preparation contains peptidases that effectively metabolize 125 IAng II. As noted previously (Bennett, 1978) , determination of binding kinetics requires that the radioligand remain intact throughout the binding assay. If this criterion cannot be met, the kinetics of the binding cannot be reliably determined, nor can the identity of the bound radioligand be established. As the extent of degradation of the radioligand increases, the error also will increase.
Addition of four peptidase inhibitors-puromycin, o-phenanthroline, PMSF, and glutamate phosphonate-dramatically reduced the metabolic degradation of 125 I-Ang II such that more than 75% of the 125 I bound to the hypothalamic membranes was intact radioligand. Associated with this improved preservation of the radioligand was the ability to demonstrate high-affinity binding of 125 I-Ang II to the hypothalamic membranes in amounts that were not significantly different from those determined using 125 I-SI Ang II (Table 3) . These four peptidase inhibitors also increased the proportion of intact radioligands bound to liver membranes (Table 3) .
Losartan displacement studies revealed that only a part of 125 I-Ang II-specific binding to hypothalamic membranes was accounted for by the AT 1 receptor, i.e., was losartan-displaceable (B max ϭ 0.19 Ϯ 0.03 fmol/mg wet weight; K d ϭ 2.0 Ϯ 0.31 nM; n ϭ 3) (Fig. 3a) . This phenomenon was true for 125 I-SI Ang II as well (Fig. 3b) , which bound to a similar number of AT 1 receptors (B max ϭ 0.25 Ϯ 0.01 fmol/mg wet weight) but, as was expected, with higher affinity (K d ϭ 0.3 Ϯ 0.08 nM). Notably, a portion of specific binding of both 125 I-Ang II and 125 I-SI Ang II in hypothalamic membranes was losartannondisplaceable (Fig. 3, a and b) . The observed losartannondisplaceable binding probably arose from degradation products of radioligands carrying 125 I, which apparently did I-SI Ang II to rat hypothalamic and liver AT 1 receptors in the presence and absence of additional protease inhibitors after 1-and 2-h incubation at 24°C, respectively Data are mean Ϯ S.E.M., n ϭ 3 to 6.
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Hypothalamic Membranes ϩ Inhibitors Liver Membranes Liver Membranes ϩ Inhibitors (Table 3 ). In contrast, virtually all specific binding of 125 I-Ang II and 125 I-SI Ang II in the liver was to the AT 1 receptor, i.e., losartan displaceable (Fig. 3, c and d) , where more than 95% of both ligands are protected from proteolytic degradation ( Table 3) .
The results of this study clearly indicate that 125 I-Ang II binds to the brain AT 1 receptor. This binding is equivalent to the binding of 125 I-SI Ang II, a synthetic peptide ligand (antagonist), considered as a standard for studies of angiotensin receptors. This observation has relevance to questions that have arisen regarding the identity of the active angiotensin in the brain (Harding and Felix, 1987; Zini et al., 1996) . These authors postulated that Ang II must be converted to Ang III in the brain to activate brain Ang II receptors, now known to be the AT 1 receptor subtype. Also see recent reviews by Bodineau et al. (2008) and Speth and Karamyan (2008) . If this supposition is correct, it would suggest two unlikely scenarios governing the interaction of Ang II with the brain AT 1 receptor: 1) Ang II does not bind to the brain AT 1 receptor; or 2) Ang II is an antagonist of the brain AT 1 receptor, or is at least a partial antagonist with respect to the pressor actions mediated by brain AT 1 receptors. The results of this study indicate that Ang II can bind to the brain AT 1 receptor with high affinity, which refutes the first of these two unlikely scenarios.
Previous work from this laboratory (Kokje et al., 2007 ) using aminopeptidase-resistant analogs of Ang II included an experiment in which a 125/127 I-labeled aminopeptidaseresistant Ang II analog, N-methyl L-Asp 1 Ang II, was administered intracerebroventricularly to rats. This peptide caused short-latency pressor and dipsogenic responses at a time when there was no discernible formation of 125/127 I-Ang III. Other aminopeptidase-resistant analogs of Ang II also showed agonistic properties with potencies equal to or greater than Ang II, with latencies equal to or shorter than Ang II (Kokje et al., 2007) . This argues strongly against the second unlikely scenario, that Ang II could be an antagonist of the brain AT 1 receptor.
It is noteworthy that 125 I-Ang III was the major component of the bound radioligand when 125 I-Ang II was incubated with hypothalamic membranes in the presence of puromycin, o-phenanthroline and PMSF but was a minor component of the bound radioligand with the further addition of glutamate phosphonate. This suggests that there is abundant aminopeptidase A activity in hypothalamic membrane preparations that escapes inhibition by the other peptidase inhibitors present in the assay buffer but which is susceptible to glutamate phosphonate at the concentration used. It is also possible that the effect of glutamate phosphonate could be due to inhibition of other acid aminopeptidases that have been reported to exist in neuronal tissues (Kelly et al., 1983; Speth and Karamyan, 2008) in view of the failure of the aminopeptidase inhibitors amastatin and bestatin to improve 125 I-Ang II binding to these hypothalamic membrane preparations. The high proportion of 125 I-Ang III binding that occurred with the addition of puromycin, o-phenanthroline, and PMSF suggests that one or more of these inhibitors was effective in blocking carboxypeptidase-and endopeptidase-mediated metabolism of 125 I-Ang II and 125 I-Ang III as well as aminopeptidase-mediated metabolism of 125 I-Ang III. The question of whether the rat brain AT 1 receptor differs from that in the periphery (for these studies, the liver was used as a representative peripheral AT 1 receptor) was not fully resolved by these studies. The K d values of both 125 IAng II and 125 I-SI Ang II tend to be lower in liver compared with brain; however, there is a possibility that the higher rate of degradation of these radioligands in the brain could explain this discrepancy. Another interesting possibility is that Ang II and Ang III might have different profiles of action, e.g., biased agonism (Violin and Lefkowitz, 2007) upon binding to the brain AT 1 receptor, which could explain discrepancies in the reported actions of angiotensins II and III in the brain.
In summary, the results of this study provide an abundance of novel and important information about the brain AT 1 receptors of the rat: as might be anticipated, rat brain AT 1 receptors bind 125 I-Ang II as well as 125 I-SI Ang II with high affinity in equivalent amounts. It is necessary to use an array of peptidase inhibitors to protect 125 I-Ang II and to a lesser extent, 125 I-SI Ang II from metabolic degradation by rat brain peptidases during radioligand binding assays. For jpet.aspetjournals.org the first time in brain angiotensin receptor binding studies, AT 1 receptor-specific binding of 125 I-Ang II was assessed as AT 1 receptor antagonist-displaceable specific binding. To date, this provides the most accurate estimation of AT 1 receptor density in rat hypothalamic membranes by virtue of establishing conditions whereby the majority of radioligand is protected from proteolytic degradation.
Overall, these results indicate that Ang II is an agonist for the rat brain AT 1 receptor akin to its characterization as an agonist for the AT 1 receptor in peripheral tissues and does not require prior conversion to Ang III to interact with the AT 1 receptor.
